23 results on '"Höidén Guthenberg I"'
Search Results
2. Growth hormone enhances proinflammatory cytokine production by monocytes in whole blood
- Author
-
Uronen-Hansson, H., Allen, M.L., Lichtarowicz-Krynska, E., Aynsley-Green, A., Cole, T.J., Höidén-Guthenberg, I., Fryklund, L., and Klein, N.
- Published
- 2003
- Full Text
- View/download PDF
3. Engineered High-Affinity Affibody Molecules Targeting Platelet-Derived Growth Factor Receptor β In Vivo
- Author
-
Lindborg, M., primary, Cortez, E., additional, Höidén-Guthenberg, I., additional, Gunneriusson, E., additional, von Hage, E., additional, Syud, F., additional, Morrison, M., additional, Abrahmsén, L., additional, Herne, N., additional, Pietras, K., additional, and Frejd, F.Y., additional
- Published
- 2011
- Full Text
- View/download PDF
4. An engineered affibody molecule with pHdependent binding to FcRn mediates extended circulatory half-lifeof a fusion protein
- Author
-
Seijsing, Johan, Lindborg, Malin, Höidén-Guthenberg, I., Bönisch, H., Gunneriusson, E., Frejd, F., Abramsén, L., Ekblad, C., Löfblom, J., Uhlén, Mathias, Gräslund, Torbjörn, Seijsing, Johan, Lindborg, Malin, Höidén-Guthenberg, I., Bönisch, H., Gunneriusson, E., Frejd, F., Abramsén, L., Ekblad, C., Löfblom, J., Uhlén, Mathias, and Gräslund, Torbjörn
- Abstract
QS 2014
5. Reduction of immunoglobulin G in mice by an affibody molecule blocking the interaction between immunoglobulin G and the neonatal Fc receptor
- Author
-
Seijsing, Johan, Johansson, P., Eklund, P., Höidén-Guthenberg, I., Frejd, F., Gräslund, Torbjörn, Seijsing, Johan, Johansson, P., Eklund, P., Höidén-Guthenberg, I., Frejd, F., and Gräslund, Torbjörn
- Abstract
QS 2014
6. Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis.
- Author
-
Klint S, Feldwisch J, Gudmundsdotter L, Dillner Bergstedt K, Gunneriusson E, Höidén Guthenberg I, Wennborg A, Nyborg AC, Kamboj AP, Peloso PM, Bejker D, and Frejd FY
- Subjects
- Humans, Antibodies, Monoclonal, Humanized, Arthritis, Psoriatic drug therapy, Hidradenitis Suppurativa chemically induced, Psoriasis drug therapy, Uveitis chemically induced
- Abstract
Psoriasis, an immune-mediated inflammatory disease, affects nearly 125 million people globally. The interleukin (IL)-17A homodimer is a key driver of psoriasis and other autoimmune diseases, including psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa, and uveitis. Treatment with monoclonal antibodies (mAbs) against IL-17A provides an improvement in the Psoriasis Area and Severity Index compared to conventional systemic agents. In this study, the Affibody
Ⓡ technology was used to identify and optimize a novel, small, biological molecule comprising three triple helical affinity domains, izokibep (previously ABY-035), for the inhibition of IL-17A signaling. Preclinical studies show that izokibep, a small 18.6 kDa IL-17 ligand trap comprising two IL-17A-specific Affibody domains and one albumin-binding domain, selectively inhibits human IL-17A in vitro and in vivo with superior potency and efficacy relative to anti-IL-17A mAbs. A Phase 1 first-in-human study was conducted to establish the safety, pharmacokinetics, and preliminary efficacy of izokibep, when administered intravenously and subcutaneously as single doses to healthy subjects, and as single intravenous and multiple subcutaneous doses to patients with psoriasis (NCT02690142; EudraCT No: 2015-004531-13). Izokibep was well tolerated with no meaningful safety concerns identified in healthy volunteers and patients with psoriasis. Rapid efficacy was seen in all psoriasis patients after one dose which further improved in patients receiving multiple doses. A therapeutic decrease in joint pain was also observed in a single patient with concurrent psoriatic arthritis. The study suggests that izokibep has the potential to safely treat IL17A-associated diseases such as psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa, and uveitis.- Published
- 2023
- Full Text
- View/download PDF
7. Affibody-Mediated Sequestration of Amyloid β Demonstrates Preventive Efficacy in a Transgenic Alzheimer's Disease Mouse Model.
- Author
-
Boutajangout A, Lindberg H, Awwad A, Paul A, Baitalmal R, Almokyad I, Höidén-Guthenberg I, Gunneriusson E, Frejd FY, Härd T, Löfblom J, Ståhl S, and Wisniewski T
- Abstract
Different strategies for treatment and prevention of Alzheimer's disease (AD) are currently under investigation, including passive immunization with anti-amyloid β (anti-Aβ) monoclonal antibodies (mAbs). Here, we investigate the therapeutic potential of a novel type of Aβ-targeting agent based on an affibody molecule with fundamentally different properties to mAbs. We generated a therapeutic candidate, denoted Z
SYM73 -albumin-binding domain (ABD; 16.8 kDa), by genetic linkage of the dimeric ZSYM73 affibody for sequestering of monomeric Aβ-peptides and an ABD for extension of its in vivo half-life. Amyloid precursor protein (APP)/PS1 transgenic AD mice were administered with ZSYM73 -ABD, followed by behavioral examination and immunohistochemistry. Results demonstrated rescued cognitive functions and significantly lower amyloid burden in the treated animals compared to controls. No toxicological symptoms or immunology-related side-effects were observed. To our knowledge, this is the first reported in vivo investigation of a systemically delivered scaffold protein against monomeric Aβ, demonstrating a therapeutic potential for prevention of AD.- Published
- 2019
- Full Text
- View/download PDF
8. Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 affibody molecule.
- Author
-
Honarvar H, Garousi J, Gunneriusson E, Höidén-Guthenberg I, Altai M, Widström C, Tolmachev V, and Frejd FY
- Subjects
- Animals, Antigens, Neoplasm chemistry, Carbonic Anhydrase IX, Carbonic Anhydrases chemistry, Carcinoma, Renal Cell genetics, Carcinoma, Renal Cell pathology, Cell Line, Tumor, Gene Expression Regulation, Neoplastic, Humans, Mice, Radiography, Technetium chemistry, Tissue Distribution, Xenograft Model Antitumor Assays, Antibodies, Monoclonal chemistry, Antigens, Neoplasm biosynthesis, Carbonic Anhydrases biosynthesis, Carcinoma, Renal Cell diagnostic imaging, Diagnostic Imaging
- Abstract
Carbonic anhydrase IX (CAIX) is a transmembrane enzyme involved in regulation of tissue pH balance. In cancer, CAIX expression is associated with tumor hypoxia. CAIX is also overexpressed in renal cell carcinoma and is a molecular target for the therapeutic antibody cG250 (girentuximab). Radionuclide imaging of CAIX expression might be used for identification of patients who may benefit from cG250 therapy and from treatment strategies for hypoxic tumors. Affibody molecules are small (7 kDa) scaffold proteins having a high potential as probes for radionuclide molecular imaging. The aim of the present study was to evaluate feasibility of in vivo imaging of CAIX-expression using radiolabeled Affibody molecules. A histidine-glutamate-histidine-glutamate-histidine-glutamate (HE)3-tag-containing CAIX-binding Affibody molecule (HE)3-ZCAIX:1 was labeled with [(99m)Tc(CO)3](+). Its binding properties were evaluated in vitro using CAIX-expressing SK-RC-52 renal carcinoma cells. (99m)Tc-(HE)3-ZCAIX:1 was evaluated in NMRI nu/nu mice bearing SK-RC-52 xenografts. The in vivo specificity test confirmed CAIX-mediated tumor targeting. (99m)Tc-(HE)3-ZCAIX:1 cleared rapidly from blood and normal tissues except for kidneys. At optimal time-point (4 h p.i.), the tumor uptake was 9.7 ± 0.7% ID/g, and tumor-to-blood ratio was 53 ± 10. Experimental imaging of CAIX-expressing SK-RC-52 xenografts at 4 h p.i. provided high contrast images. The use of radioiodine label for ZCAIX:1 enabled the reduction of renal uptake, but resulted in significantly lower tumor uptake and tumor-to-blood ratio. Results of the present study suggest that radiolabeled Affibody molecules are promising probes for imaging of CAIX-expression in vivo.
- Published
- 2015
- Full Text
- View/download PDF
9. Early implementation of QbD in biopharmaceutical development: a practical example.
- Author
-
Zurdo J, Arnell A, Obrezanova O, Smith N, Gómez de la Cuesta R, Gallagher TR, Michael R, Stallwood Y, Ekblad C, Abrahmsén L, and Höidén-Guthenberg I
- Subjects
- Humans, Biopharmaceutics methods, Drug Design, Drug Industry methods
- Abstract
In drug development, the "onus" of the low R&D efficiency has been put traditionally onto the drug discovery process (i.e., finding the right target or "binding" functionality). Here, we show that manufacturing is not only a central component of product success, but also that, by integrating manufacturing and discovery activities in a "holistic" interpretation of QbD methodologies, we could expect to increase the efficiency of the drug discovery process as a whole. In this new context, early risk assessment, using developability methodologies and computational methods in particular, can assist in reducing risks during development in a cost-effective way. We define specific areas of risk and how they can impact product quality in a broad sense, including essential aspects such as product efficacy and patient safety. Emerging industry practices around developability are introduced, including some specific examples of applications to biotherapeutics. Furthermore, we suggest some potential workflows to illustrate how developability strategies can be introduced in practical terms during early drug development in order to mitigate risks, reduce drug attrition and ultimately increase the robustness of the biopharmaceutical supply chain. Finally, we also discuss how the implementation of such methodologies could accelerate the access of new therapeutic treatments to patients in the clinic.
- Published
- 2015
- Full Text
- View/download PDF
10. An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein.
- Author
-
Seijsing J, Lindborg M, Höidén-Guthenberg I, Bönisch H, Guneriusson E, Frejd FY, Abrahmsén L, Ekblad C, Löfblom J, Uhlén M, and Gräslund T
- Subjects
- Animals, Binding, Competitive, Carrier Proteins genetics, Cell Line, Tumor, Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Half-Life, HeLa Cells, Histocompatibility Antigens Class I genetics, Humans, Hydrogen-Ion Concentration, Male, Mice, Inbred Strains, Peptide Library, Protein Binding, Receptors, Fc genetics, Recombinant Fusion Proteins blood, Carrier Proteins metabolism, Histocompatibility Antigens Class I metabolism, Receptors, Fc metabolism, Recombinant Fusion Proteins metabolism, Recombinant Fusion Proteins pharmacokinetics
- Abstract
Proteins endocytosed from serum are degraded in the lysosomes. However, serum albumin (SA) and IgG, through its Fc part, bind to the neonatal Fc receptor (FcRn) at low pH in the endosome after endocytosis, and are transported back to the cellular surface, where they are released into the bloodstream, resulting in an extended serum circulation time. Association with Fc or SA has been used to prolong the in vivo half-life of biopharmaceuticals, using the interaction with FcRn to improve treatment regimens. This has been achieved either directly, by fusion or conjugation to Fc or SA, or indirectly, using SA-binding proteins. The present work takes this principle one step further, presenting small affinity proteins that bind directly to FcRn, mediating extension of the serum half-life of fused biomolecules. Phage display technology was used to select affibody molecules that can bind to FcRn in the pH-dependent manner required for rescue by FcRn. The biophysical and binding properties were characterized in vitro, and the affibody molecules were found to bind to FcRn more strongly at low pH than at neutral pH. Attachment of the affibody molecules to a recombinant protein, already engineered for increased half-life, resulted in a nearly threefold longer half-life in mice. These tags should have general use as fusion partners to biopharmaceuticals to extend their half-lives in vivo.
- Published
- 2014
- Full Text
- View/download PDF
11. Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification.
- Author
-
Malm M, Kronqvist N, Lindberg H, Gudmundsdotter L, Bass T, Frejd FY, Höidén-Guthenberg I, Varasteh Z, Orlova A, Tolmachev V, Ståhl S, and Löfblom J
- Subjects
- Alanine, Animals, Biosensing Techniques, Cell Line, Tumor, Cell Proliferation drug effects, Cell Surface Display Techniques, Circular Dichroism, Female, Humans, Inhibitory Concentration 50, Ligands, Mice, Mutation, Peptide Library, Phosphorylation drug effects, Protein Binding, Receptor, ErbB-3 chemistry, Receptor, ErbB-3 genetics, Recombinant Fusion Proteins metabolism, Neoplasms metabolism, Receptor, ErbB-3 metabolism, Recombinant Fusion Proteins pharmacology, Signal Transduction drug effects
- Abstract
The HER3 receptor is implicated in the progression of various cancers as well as in resistance to several currently used drugs, and is hence a potential target for development of new therapies. We have previously generated Affibody molecules that inhibit heregulin-induced signaling of the HER3 pathways. The aim of this study was to improve the affinity of the binders to hopefully increase receptor inhibition efficacy and enable a high receptor-mediated uptake in tumors. We explored a novel strategy for affinity maturation of Affibody molecules that is based on alanine scanning followed by design of library diversification to mimic the result from an error-prone PCR reaction, but with full control over mutated positions and thus less biases. Using bacterial surface display and flow-cytometric sorting of the maturation library, the affinity for HER3 was improved more than 30-fold down to 21 pM. The affinity is among the higher that has been reported for Affibody molecules and we believe that the maturation strategy should be generally applicable for improvement of affinity proteins. The new binders also demonstrated an improved thermal stability as well as complete refolding after denaturation. Moreover, inhibition of ligand-induced proliferation of HER3-positive breast cancer cells was improved more than two orders of magnitude compared to the previously best-performing clone. Radiolabeled Affibody molecules showed specific targeting of a number of HER3-positive cell lines in vitro as well as targeting of HER3 in in vivo mouse models and represent promising candidates for future development of targeted therapies and diagnostics.
- Published
- 2013
- Full Text
- View/download PDF
12. Cellular effects of HER3-specific affibody molecules.
- Author
-
Göstring L, Malm M, Höidén-Guthenberg I, Frejd FY, Ståhl S, Löfblom J, and Gedda L
- Subjects
- Binding, Competitive, Blotting, Western, Cell Line, Tumor, Cell Proliferation, Enzyme-Linked Immunosorbent Assay, Extracellular Signal-Regulated MAP Kinases metabolism, Flow Cytometry, Fluorescent Antibody Technique, Humans, Ligands, Microscopy, Confocal, Neuregulin-1 metabolism, Phosphorylation, Protein Binding, Proto-Oncogene Proteins c-akt metabolism, Receptors, Cell Surface metabolism, Receptor, ErbB-3 metabolism, Recombinant Fusion Proteins metabolism
- Abstract
Recent studies have led to the recognition of the epidermal growth factor receptor HER3 as a key player in cancer, and consequently this receptor has gained increased interest as a target for cancer therapy. We have previously generated several Affibody molecules with subnanomolar affinity for the HER3 receptor. Here, we investigate the effects of two of these HER3-specific Affibody molecules, Z05416 and Z05417, on different HER3-overexpressing cancer cell lines. Using flow cytometry and confocal microscopy, the Affibody molecules were shown to bind to HER3 on three different cell lines. Furthermore, the receptor binding of the natural ligand heregulin (HRG) was blocked by addition of Affibody molecules. In addition, both molecules suppressed HRG-induced HER3 and HER2 phosphorylation in MCF-7 cells, as well as HER3 phosphorylation in constantly HER2-activated SKBR-3 cells. Importantly, Western blot analysis also revealed that HRG-induced downstream signalling through the Ras-MAPK pathway as well as the PI3K-Akt pathway was blocked by the Affibody molecules. Finally, in an in vitro proliferation assay, the two Affibody molecules demonstrated complete inhibition of HRG-induced cancer cell growth. Taken together, our findings demonstrate that Z05416 and Z05417 exert an anti-proliferative effect on two breast cancer cell lines by inhibiting HRG-induced phosphorylation of HER3, suggesting that the Affibody molecules are promising candidates for future HER3-targeted cancer therapy.
- Published
- 2012
- Full Text
- View/download PDF
13. Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules.
- Author
-
Kronqvist N, Malm M, Göstring L, Gunneriusson E, Nilsson M, Höidén Guthenberg I, Gedda L, Frejd FY, Ståhl S, and Löfblom J
- Subjects
- Amino Acid Sequence, Antibody Affinity genetics, Humans, Molecular Sequence Data, Recombinant Fusion Proteins chemistry, Recombinant Fusion Proteins genetics, Staphylococcus, Antibody Affinity immunology, Peptide Library, Receptor, ErbB-3 immunology, Recombinant Fusion Proteins biosynthesis
- Abstract
Emerging evidence suggests that the catalytically inactive ErbB3 (HER3) protein plays a fundamental role in normal tyrosine kinase receptor signaling as well as in aberrant functioning of these signaling pathways, resulting in several forms of human cancers. ErbB3 has recently also been implicated in resistance to ErbB2-targeting therapies. Here we report the generation of high-affinity ErbB3-specific Affibody molecules intended for future molecular imaging and biotherapeutic applications. Using a high-complexity phage-displayed Affibody library, a number of ErbB3 binders were isolated and specific cell-binding activity was demonstrated in immunofluorescence microscopic studies. Subsequently, a second-generation library was constructed based on sequences of the candidates from the phage display selection. By exploiting the sensitive affinity discrimination capacity of a novel bacterial surface display technology, the affinity of candidate Affibody molecules was further increased down to subnanomolar affinity. In summary, the demonstrated specific targeting of native ErbB3 receptor on human cancer cell lines as well as competition with the heregulin/ErbB3 interaction indicates that these novel biological agents may become useful tools for diagnostic and therapeutic targeting of ErbB3-expressing cancers. Our studies also highlight the powerful approach of combining the advantages of different display technologies for generation of functional high-affinity protein-based binders. Potential future applications, such as radionuclide-based diagnosis and treatment of human cancers are discussed.
- Published
- 2011
- Full Text
- View/download PDF
14. Design of an optimized scaffold for affibody molecules.
- Author
-
Feldwisch J, Tolmachev V, Lendel C, Herne N, Sjöberg A, Larsson B, Rosik D, Lindqvist E, Fant G, Höidén-Guthenberg I, Galli J, Jonasson P, and Abrahmsén L
- Subjects
- Amino Acid Sequence, Amino Acid Substitution, Breast Neoplasms chemistry, Female, Humans, Immunohistochemistry, Molecular Sequence Data, Protein Structure, Tertiary, Recombinant Fusion Proteins genetics, Recombinant Fusion Proteins immunology, Protein Engineering, Receptor, ErbB-2 immunology, Recombinant Fusion Proteins chemistry
- Abstract
Affibody molecules are non-immunoglobulin-derived affinity proteins based on a three-helical bundle protein domain. Here, we describe the design process of an optimized Affibody molecule scaffold with improved properties and a surface distinctly different from that of the parental scaffold. The improvement was achieved by applying an iterative process of amino acid substitutions in the context of the human epidermal growth factor receptor 2 (HER2)-specific Affibody molecule Z(HER2:342). Replacements in the N-terminal region, loop 1, helix 2 and helix 3 were guided by extensive structural modeling using the available structures of the parent Z domain and Affibody molecules. The effect of several single substitutions was analyzed followed by combination of up to 11 different substitutions. The two amino acid substitutions N23T and S33K accounted for the most dramatic improvements, including increased thermal stability with elevated melting temperatures of up to +12 degrees C. The optimized scaffold contains 11 amino acid substitutions in the nonbinding surface and is characterized by improved thermal and chemical stability, as well as increased hydrophilicity, and enables generation of identical Affibody molecules both by chemical peptide synthesis and by recombinant bacterial expression. A HER2-specific Affibody tracer, [MMA-DOTA-Cys61]-Z(HER2:2891)-Cys (ABY-025), was produced by conjugating MMA-DOTA (maleimide-monoamide-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) to the peptide produced either chemically or in Escherichia coli. ABY-025 showed high affinity and specificity for HER2 (equilibrium dissociation constant, K(D), of 76 pM) and detected HER2 in tissue sections of SKOV-3 xenograft and human breast tumors. The HER2-binding capacity was fully retained after three cycles of heating to 90 degrees C followed by cooling to room temperature. Furthermore, the binding surfaces of five Affibody molecules targeting other proteins (tumor necrosis factor alpha, insulin, Taq polymerase, epidermal growth factor receptor or platelet-derived growth factor receptor beta) were grafted onto the optimized scaffold, resulting in molecules with improved thermal stability and a more hydrophilic nonbinding surface., ((c) 2010 Elsevier Ltd. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
15. Quantification of internalization of EGFR-binding Affibody molecules: Methodological aspects.
- Author
-
Göstring L, Chew MT, Orlova A, Höidén-Guthenberg I, Wennborg A, Carlsson J, and Frejd FY
- Subjects
- Biological Transport, Carbocyanines, Cell Line, Tumor, Fluorescent Dyes, Humans, Indium Radioisotopes, Kinetics, Ligands, Succinimides, Endocytosis, ErbB Receptors metabolism, Flow Cytometry methods, Microscopy, Confocal methods, Microscopy, Fluorescence methods, Recombinant Fusion Proteins metabolism
- Abstract
Tumor cell internalization of targeting agents is of interest, since internalization influences the local retention time of a radionuclide and thereby imaging quality in PET and SPECT and effects of radionuclide therapy. In cases where nuclear methods are not applicable at the cellular level, quantitative fluorescent techniques are useful as described in this article. Two fluorescence-based methods to study cellular internalization were applied: the CypHer and the Alexa488-quenching methods, both utilized in fluorescence microscopy and flow cytometry. Two EGFR-binding Affibody molecules were analyzed in A431 cells: the monomer Z1907 and the dimer (Z1907)2. EGF, cetuximab and non-specific Affibody molecules were used as controls. For comparison, internalization of 111In-labeled Z1907 was studied with the acid wash internalization assay. The Cypher method is straightforward, but requires equal labeling of all compounds for accurate quantification. The Alexa488-quenching method is preferable since it is independent of the dye-to-protein ratio. According to this method, about 45% of EGF and 19-24% of the bound Affibody molecules and cetuximab were internalized within one hour. Similar results were seen with 111In-Z1907 in the acid wash method, while (Z1907)2 was not removed by acid and thus could not be studied this way. The fluorescence-based Alexa488-quenching method is well suited to quantitatively analyze internalization of targeting agents, also those that resist acid wash. The internalized fraction showed that both the monomeric and dimeric Affibody molecules are expected to give good uptake and thereby good retention of metallic radionuclides which will render good tumor to background values.
- Published
- 2010
- Full Text
- View/download PDF
16. Selection of affibody molecules to the ligand-binding site of the insulin-like growth factor-1 receptor.
- Author
-
Li J, Lundberg E, Vernet E, Larsson B, Höidén-Guthenberg I, and Gräslund T
- Subjects
- Animals, Antibodies, Monoclonal genetics, Antibodies, Monoclonal immunology, Cell Line, Tumor, Enzyme-Linked Immunosorbent Assay, Humans, Mice, Receptor, IGF Type 1 immunology, Single-Chain Antibodies genetics, Single-Chain Antibodies immunology, Antibodies, Monoclonal chemistry, Receptor, IGF Type 1 chemistry, Single-Chain Antibodies chemistry
- Abstract
Affibody molecules binding to the site of hormone interaction in IGF-1R (insulin-like growth factor-1 receptor) were successfully selected by phage-display technology employing a competitive-elution strategy during biopanning, whereby release of receptor-bound phagemids was accomplished by competition with IGF-1 (insulin-like growth factor-1). In non-competitive selections, the elution of receptor-bound phagemids was performed by imidazole or low-pH incubation, which also resulted in the isolation of affibody molecules that could bind to the receptor. An ELISA-based assay showed that the affibody molecules generated by IGF-1 competition during elution, in addition to affibody molecules generated in the non-competitive selections, could compete with IGF-1 for binding to the receptor. The affinities of the isolated variants to IGF-1R-overexpressing MCF-7 cells were determined and ranged from high nanomolar to 2.3 nM. The most promising variant, Z4:40, was shown to recognize IGF-1R efficiently in several different contexts: in analyses based on flow cytometry, fluorescence microscopy and receptor pull-down from cell extracts. In addition, when Z4:40 was added to the medium of MCF-7 cells that were dependent on IGF-1 for efficient growth, it was found to have a dose-dependent growth-inhibitory effect on the cells. Applications of affibody-based reagents for quantitative and qualitative analyses of IGF-1R status, as well as applications of affibody-based reagents for therapy, are discussed.
- Published
- 2010
- Full Text
- View/download PDF
17. Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule.
- Author
-
Friedman M, Orlova A, Johansson E, Eriksson TL, Höidén-Guthenberg I, Tolmachev V, Nilsson FY, and Ståhl S
- Subjects
- Animals, Antibody Specificity, Cell Line, Tumor, ErbB Receptors analysis, Humans, Indium Radioisotopes metabolism, Mice, Mice, Inbred BALB C, Neoplasm Transplantation, Neoplasms diagnosis, Transplantation, Heterologous, Antibodies chemistry, Antibodies genetics, Antibodies metabolism, Directed Molecular Evolution, ErbB Receptors metabolism
- Abstract
The epidermal growth factor receptor 1 (EGFR) is overexpressed in various malignancies and is associated with a poor patient prognosis. A small, receptor-specific, high-affinity imaging agent would be a useful tool in diagnosing malignant tumors and in deciding upon treatment and assessing the response to treatment. We describe here the affinity maturation procedure for the generation of Affibody molecules binding with high affinity and specificity to EGFR. A library for affinity maturation was constructed by rerandomization of selected positions after the alignment of first-generation binding variants. New binders were selected with phage display technology, using a single oligonucleotide in a single-library effort, and the best second-generation binders had an approximately 30-fold improvement in affinity (K(d)=5-10 nM) for the soluble extracellular domain of EGFR in biospecific interaction analysis using Biacore. The dissociation equilibrium constant, K(d), was also determined for the Affibody with highest affinity using EGFR-expressing A431 cells in flow cytometric analysis (K(d)=2.8 nM). A retained high specificity for EGFR was verified by a dot blot assay showing staining only of EGFR proteins among a panel of serum proteins and other EGFR family member proteins (HER2, HER3, and HER4). The EGFR-binding Affibody molecules were radiolabeled with indium-111, showing specific binding to EGFR-expressing A431 cells and successful targeting of the A431 tumor xenografts with 4-6% injected activity per gram accumulated in the tumor 4 h postinjection.
- Published
- 2008
- Full Text
- View/download PDF
18. Affibody-mediated transferrin depletion for proteomics applications.
- Author
-
Grönwall C, Sjöberg A, Ramström M, Höidén-Guthenberg I, Hober S, Jonasson P, and Ståhl S
- Subjects
- Blotting, Western, Chromatography, Affinity, Enzyme-Linked Immunosorbent Assay, Humans, Immunoglobulin G blood, Immunoglobulin G cerebrospinal fluid, Immunoglobulin G metabolism, Peptide Library, Protein Binding, Protein Engineering methods, Serum Albumin cerebrospinal fluid, Serum Albumin metabolism, Transferrin cerebrospinal fluid, Ligands, Proteomics methods, Transferrin metabolism
- Abstract
An Affibody (Affibody) ligand with specific binding to human transferrin was selected by phage display technology from a combinatorial protein library based on the staphylococcal protein A (SpA)-derived Z domain. Strong and selective binding of the selected Affibody ligand to transferrin was demonstrated using biosensor technology and dot blot analysis. Impressive specificity was demonstrated as transferrin was the only protein recovered by affinity chromatography from human plasma. Efficient Affibody-mediated capture of transferrin, combined with IgG- and HSA-depletion, was demonstrated for human plasma and cerebrospinal fluid (CSF). For plasma, 85% of the total transferrin content in the samples was depleted after only two cycles of transferrin removal, and for CSF, 78% efficiency was obtained in single-step depletion. These results clearly suggest a potential for the development of Affibody-based resins for the removal of abundant proteins in proteomics analyses.
- Published
- 2007
- Full Text
- View/download PDF
19. Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples.
- Author
-
Lundberg E, Höidén-Guthenberg I, Larsson B, Uhlén M, and Gräslund T
- Subjects
- Binding Sites, Antibody, Cell Line, Cell Line, Tumor, Cell Separation, Flow Cytometry, Humans, Immunoprecipitation, Indicators and Reagents, Receptor, ErbB-2 biosynthesis, Receptor, ErbB-2 genetics, Receptor, ErbB-2 metabolism, Receptor, ErbB-2 immunology, Recombinant Fusion Proteins metabolism, Transplantation, Heterologous immunology
- Abstract
Affibody molecules are a class of small and robust affinity proteins that can be generated to interact with a variety of antigens, thus having the potential to provide useful tools for biotechnological research and diagnostic applications. In this study, we have investigated Affibody-based reagents interacting specifically with the tyrosine kinase receptor HER2. A head-to-tail dimeric construct was site-specifically conjugated with different fluorescent and enzymatic groups resulting in reagents that were used for detection and quantification. The amount of cell surface expressed HER2 on eleven (11) well characterized cell lines was quantified relative to each other by flow cytometry and shown to correlate well with results from parallel analyses of HER2 mRNA levels measured by real-time PCR. Further, immunofluorescence microscopy studies of the cell lines and immunohistochemical analyses of cryosections of HER2 expressing SKOV-3 xenografts showed strong staining of the plasma membrane of tumor cells with little background staining. Full-length HER2 protein could also be efficiently recovered from a cell extract by an immunoprecipitation procedure, using an Affibody ligand-based resin. These novel non-IgG derived reagents could be used to detect and quantify HER2 expression. By adapting the methods for use with Affibody molecules binding to other cell surface receptors, it is anticipated that also these receptors can be detected and quantified in a similar manner.
- Published
- 2007
- Full Text
- View/download PDF
20. Tumor imaging using a picomolar affinity HER2 binding affibody molecule.
- Author
-
Orlova A, Magnusson M, Eriksson TL, Nilsson M, Larsson B, Höidén-Guthenberg I, Widström C, Carlsson J, Tolmachev V, Ståhl S, and Nilsson FY
- Subjects
- Amino Acid Sequence, Animals, Antibodies genetics, Antibody Specificity, Biosensing Techniques methods, Cell Line, Tumor, Female, Humans, Image Processing, Computer-Assisted methods, Immunohistochemistry, Iodine Radioisotopes, Mice, Mice, Inbred BALB C, Microscopy, Fluorescence, Molecular Sequence Data, Neuroblastoma metabolism, Ovarian Neoplasms metabolism, Radionuclide Imaging, Receptor, ErbB-2 genetics, Receptor, ErbB-2 immunology, Receptor, ErbB-2 metabolism, Tissue Distribution, Transplantation, Heterologous, Antibodies metabolism, Neuroblastoma diagnostic imaging, Ovarian Neoplasms diagnostic imaging, Receptor, ErbB-2 biosynthesis
- Abstract
The detection of cell-bound proteins that are produced due to aberrant gene expression in malignant tumors can provide important diagnostic information influencing patient management. The use of small radiolabeled targeting proteins would enable high-contrast radionuclide imaging of cancers expressing such antigens if adequate binding affinity and specificity could be provided. Here, we describe a HER2-specific 6 kDa Affibody molecule (hereinafter denoted Affibody molecule) with 22 pmol/L affinity that can be used for the visualization of HER2 expression in tumors in vivo using gamma camera. A library for affinity maturation was constructed by re-randomization of relevant positions identified after the alignment of first-generation variants of nanomolar affinity (50 nmol/L). One selected Affibody molecule, Z(HER2:342) showed a >2,200-fold increase in affinity achieved through a single-library affinity maturation step. When radioiodinated, the affinity-matured Affibody molecule showed clear, high-contrast visualization of HER2-expressing xenografts in mice as early as 6 hours post-injection. The tumor uptake at 4 hours post-injection was improved 4-fold (due to increased affinity) with 9% of the injected dose per gram of tissue in the tumor. Affibody molecules represent a new class of affinity molecules that can provide small sized, high affinity cancer-specific ligands, which may be well suited for tumor imaging.
- Published
- 2006
- Full Text
- View/download PDF
21. Selective enrichment of monospecific polyclonal antibodies for antibody-based proteomics efforts.
- Author
-
Agaton C, Falk R, Höidén Guthenberg I, Göstring L, Uhlén M, and Hober S
- Subjects
- Antibodies isolation & purification, Antibody Specificity, Blotting, Western, Antibodies chemistry, Proteomics
- Abstract
A high stringency protocol, suitable for systematic purification of polyclonal antibodies, is described. The procedure is designed to allow the generation of target protein-specific antibodies suitable for functional annotation of proteins. Antibodies were generated by immunization with recombinantly produced affinity-tagged target proteins. To obtain stringent recovery of the antibodies, a two-step affinity chromatography principle was devised to first deplete the affinity tag-specific antibodies followed by a second step for affinity capture of the target protein-specific antibodies. An analytical dot-blot array system was developed to analyze the cross-reactivity of the affinity-purified antibodies. The results suggest that the protocol can be used in a highly parallel and automated manner to generate mono-specific polyclonal antibodies for large-scale, antibody-based proteomics efforts, i.e. affinity proteomics.
- Published
- 2004
- Full Text
- View/download PDF
22. Affibody-beta-galactosidase immunoconjugates produced as soluble fusion proteins in the Escherichia coli cytosol.
- Author
-
Rönnmark J, Kampf C, Asplund A, Höidén-Guthenberg I, Wester K, Pontén F, Uhlén M, and Nygren PA
- Subjects
- Biosensing Techniques, Cytosol metabolism, Enzyme-Linked Immunosorbent Assay, Escherichia coli genetics, Humans, Immunoconjugates isolation & purification, Immunoglobulin A immunology, Immunohistochemistry, Immunoconjugates immunology, Immunoglobulin A analysis, Recombinant Fusion Proteins immunology, beta-Galactosidase immunology
- Abstract
Recombinant immunoconjugates constitute a novel class of immunoassay reagents produced by genetic fusion between an antigen recognizing moiety and a reporter enzyme or fluorescent protein, obviating the need for chemical coupling. In this work, we describe the construction, Escherichia coli production and characterization of recombinant beta-galactosidase (beta-gal)-based immunoconjugates directed to human immunoglobulin A (IgA). As the antigen recognizing moieties, either monovalent or dimeric (head-to-tail) versions of an IgA-specific affibody (Z(IgA1)) were used, previously selected in vitro from a protein library based on combinatorial engineering of a single staphylococcal protein A domain. To increase the likelihood of proper presentation on the assembled homotetrameric enzyme surface, the affibody moieties were linked to the N-terminus of the enzyme subunits via a heptapeptide linker sequence. The two resulting immunoconjugates Z(IgA1)-beta-gal and (Z(IgA1))(2)-beta-gal, containing four and eight affibody moieties per enzyme, respectively, could be expressed as soluble and proteolytically stable proteins intracellularly in E. coli from where they were purified to high purity by a single anion exchange chromatography step. The yields of immunoconjugates were in the range 200-400 mg/l culture. Biosensor-binding studies showed that both the Z(IgA1)-beta-gal and (Z(IgA1))(2)-beta-gal immunoconjugates were capable of selective IgA-recognition, but with an apparent higher binding affinity for the variant containing divalent affibody moieties, presumably due to avidity effects. The applicability of this class of recombinant immunoconjugates was demonstrated by IgA detection in enzyme-linked immunosorbent assay (ELISA) and dot-blot analyses. In addition, using human kidney biopsy samples from a nephropathy patient, IgA depositions in glomeruli could be detected by immunohistochemistry with low background staining of tissue.
- Published
- 2003
- Full Text
- View/download PDF
23. Affinity proteomics for systematic protein profiling of chromosome 21 gene products in human tissues.
- Author
-
Agaton C, Galli J, Höidén Guthenberg I, Janzon L, Hansson M, Asplund A, Brundell E, Lindberg S, Ruthberg I, Wester K, Wurtz D, Höög C, Lundeberg J, Ståhl S, Pontén F, and Uhlén M
- Subjects
- Antibodies, Computational Biology, Expressed Sequence Tags, Humans, Organ Specificity, Pilot Projects, Recombinant Proteins immunology, Recombinant Proteins metabolism, Tissue Array Analysis, Chromosomes, Human, Pair 21 metabolism, Proteome metabolism
- Abstract
Here we show that an affinity proteomics strategy using affinity-purified antibodies raised against recombinant human protein fragments can be used for chromosome-wide protein profiling. The approach is based on affinity reagents raised toward bioinformatics-designed protein epitope signature tags corresponding to unique regions of individual gene loci. The genes of human chromosome 21 identified by the genome efforts were investigated, and the success rates for de novo cloning, protein production, and antibody generation were 85, 76, and 56%, respectively. Using human tissue arrays, a systematic profiling of protein expression and subcellular localization was undertaken for the putative gene products. The results suggest that this affinity proteomics strategy can be used to produce a proteome atlas, describing distribution and expression of proteins in normal tissues as well as in common cancers and other forms of diseased tissues.
- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.